Spironolactone for Acne: History, Development, and How It Works

Where Spironolactone Came From: A Drug That Reinvented Itself

Spironolactone did not begin its life as a dermatology drug. It was developed as a synthetic steroid antagonist specifically designed to block aldosterone, the mineralocorticoid hormone that governs sodium retention and blood pressure. Searle Laboratories introduced the compound in 1957 after chemists working on steroid synthesis noticed that certain 17-spirolactone derivatives had potent aldosterone-blocking activity. The FDA approved spironolactone for the treatment of hypertension, edema, and hyperaldosteronism in 1960.

For the first two decades, its life was purely cardiovascular. Then something unexpected appeared in the clinical data.

The Accidental Dermatology Discovery

Clinicians treating women for hypertension and heart failure began reporting a consistent side effect: reduced body hair and changes in skin oiliness. These were not adverse events in men. They were appearing almost exclusively in women, and in some cases the women found them welcome. By the late 1970s, researchers had started to map the mechanism. Spironolactone, it turned out, was not just blocking aldosterone. Its chemical structure was close enough to testosterone that it competitively bound to androgen receptors throughout the body, including in the sebaceous glands and hair follicles of the skin.

The first formal reports of spironolactone being used deliberately for hirsutism and androgen-driven skin conditions appeared in the early 1980s. A 1982 paper in the Journal of the American Academy of Dermatology described its use in women with hyperandrogenism, documenting reductions in sebum production and acne lesion counts. This was a repurposing story driven by patient observation, not industry investment, which is part of why the acne indication never received formal FDA approval. Off-label prescribing became standard practice, built on decades of accumulating evidence rather than a single industry-sponsored trial.

Why the FDA Label Never Changed

The economics of drug approval discourage manufacturers from seeking new indications for off-patent generics. Spironolactone lost patent protection decades ago. There is no financial incentive for any single company to run the Phase III trials needed for an FDA acne label, so the drug remains off-label for skin despite being recommended in multiple clinical guidelines. The American Academy of Dermatology and the American Academy of Family Physicians both include it in their acne management algorithms for adult women.

How Spironolactone Actually Works in Your Skin

The short answer: spironolactone reduces the androgen signal that tells your sebaceous glands to produce excess oil. Less oil means fewer clogged pores, less bacterial growth, and fewer inflammatory lesions.

The longer answer involves three distinct mechanisms working at once.

Mechanism 1: Androgen Receptor Blockade

Spironolactone and its active metabolite canrenone competitively bind androgen receptors, including the AR expressed in sebaceous gland cells and dermal papilla cells of hair follicles. When testosterone or dihydrotestosterone (DHT) would normally bind these receptors and signal increased sebum synthesis, spironolactone gets there first and produces no downstream signal. The receptor is occupied but not activated.

DHT is the more potent androgen at the skin level. It is roughly five times more potent than testosterone at androgen receptors, and it is produced locally in sebaceous glands by the enzyme 5-alpha reductase acting on circulating testosterone. Spironolactone blocks the receptor that DHT is trying to reach. It does not suppress DHT production at the source, but blocking the receptor achieves a similar functional outcome for the skin.

Mechanism 2: Inhibition of Androgen Synthesis

Separately from receptor blockade, spironolactone partially inhibits enzymes involved in androgen biosynthesis, including 17-hydroxylase and 17,20-lyase, both of which are steps in the pathway that produces testosterone from cholesterol in the adrenal glands and ovaries. This effect is weaker than its receptor-blocking activity, but it contributes to the overall reduction in androgen signaling, particularly in women with adrenal hyperandrogenism.

Mechanism 3: 5-Alpha Reductase Inhibition

Some evidence suggests spironolactone also weakly inhibits 5-alpha reductase, the enzyme that converts testosterone to the more potent DHT in peripheral tissues including the skin. This triple-layer action, receptor blockade plus synthesis reduction plus conversion inhibition, may explain why the drug works even in women whose serum androgen levels test within the normal range. The skin has its own androgen metabolism. You do not need elevated bloodwork to have androgen-driven acne.

The Evidence Base: What Clinical Trials Actually Show

Spironolactone's acne evidence is built on decades of observational data, retrospective chart reviews, and a smaller number of prospective trials. The evidence base is real but imperfect, and it is worth knowing which is which.

The Layton 2017 Study

The most frequently cited prospective data comes from Layton et al., published in the British Journal of Dermatology in 2017. This study evaluated spironolactone at 100 to 200 mg per day in adult women with hormonal acne, defined as acne predominantly on the lower face, jawline, and neck, with or without premenstrual flares. The study found statistically significant reductions in both inflammatory and noninflammatory lesion counts. Roughly 85% of participants reported subjective improvement in acne severity by 6 months. Dose reductions to 50 mg were associated with sustained benefit in women who had achieved initial clearance.

SAHA and PCOS Subgroups

Women with PCOS, congenital adrenal hyperplasia, or idiopathic hyperandrogenism tend to show stronger responses in published case series. A 2017 review in Fertility and Sterility noted that spironolactone at 100 mg per day reduced the Ferriman-Gallwey hirsutism score by a clinically meaningful margin in women with PCOS, with parallel improvements in acne in the same cohort. For women in this group, spironolactone addresses both the skin manifestation and the underlying hormonal driver simultaneously.

What the Evidence Cannot Yet Tell Us

Women have been under-represented in the foundational pharmacology trials for this drug. Most early safety and dosing data were derived from cardiovascular populations, which skewed heavily male. Pharmacokinetic data specific to women show that canrenone exposure (the active metabolite) varies across the menstrual cycle due to changes in plasma protein binding driven by estrogen and progesterone fluctuations. This means the effective drug level may be somewhat higher in the luteal phase than in the follicular phase for pre-menopausal women, though clinical dosing protocols do not yet account for this difference. This is an evidence gap, not a theoretical concern.

A clinically useful way to frame the evidence level for each use case in women:

| Clinical scenario | Evidence level | Notes | |---|---|---| | Adult female hormonal acne (lower face/jaw) | Moderate (prospective studies, systematic reviews) | Layton 2017 and multiple cohort studies | | Acne with PCOS | Moderate | Parallel hirsutism benefit; less placebo-controlled RCT data | | Perimenopausal acne | Low to moderate | Extrapolated from reproductive-age data; dedicated trials absent | | Postmenopausal acne | Low | Case series only; use with caution if also on MHT | | Acne in pregnancy | Contraindicated | No safety data; known teratogen in animal models |

Spironolactone Across Your Life Stage

Hormonal acne does not behave the same way at 22, 35, 45, or 52. Neither does spironolactone's risk-benefit calculation.

Reproductive Years (Ages 18 to 40, Not Pregnant or Planning Pregnancy)

This is where most of the published acne data sit. Women in this group are the target population studied by Layton and most observational series. Starting doses of 50 mg per day are typical, with titration to 100 mg at 4 to 8 weeks if response is partial. Some clinicians go to 150 or 200 mg for severe or treatment-resistant cases. Many prescribers co-prescribe an oral contraceptive pill, both to prevent pregnancy (mandatory, see below) and because the progestin and estrogen in combined OCP can independently reduce androgen levels. The combined OCP plus spironolactone approach may produce faster clearance than either alone.

Trying to Conceive

Spironolactone must be stopped before attempting conception. The drug is teratogenic in animal models and is classified as FDA Pregnancy Category C/D depending on trimester, with anti-androgenic effects that could interfere with male fetal genital development. A washout period of at least one month before attempting pregnancy is the standard clinical recommendation, though the drug's half-life is short (approximately 1.4 hours for spironolactone itself, though the active metabolite canrenone has a half-life closer to 16 hours). Discuss timing with your prescriber.

Perimenopause (Typically Ages 45 to 55)

Perimenopausal acne is under-recognized. As estrogen begins to fluctuate and eventually fall, the relative balance shifts toward androgens even if absolute androgen levels are not rising. Many women experience their worst adult acne in their mid-to-late 40s, often on the jawline and chin, exactly the distribution spironolactone targets. Spironolactone remains an option in this stage, though the evidence is extrapolated from reproductive-age trials. If a woman is also being considered for menopausal hormone therapy (MHT), her prescriber should review the androgenic potency of any progestogen in the MHT regimen, since some synthetic progestogens (such as levonorgestrel or norgestrel) may worsen androgen-driven skin changes.

Post-Menopause

Post-menopausal androgen-driven acne is uncommon but does occur, particularly in women with persistent adrenal androgen production or those using testosterone therapy for hypoactive sexual desire disorder or energy. Spironolactone can address both the acne and offset some androgenic side effects of low-dose testosterone. Pregnancy is not a concern in confirmed post-menopause, removing the key contraindication. Monitoring for hyperkalemia remains important at any age.

Pregnancy, Lactation, and Contraception: The Non-Negotiables

Spironolactone is contraindicated in pregnancy. This is not a relative caution. Animal studies show that spironolactone's anti-androgenic effects can feminize male fetuses, and there is no human safety data that counters this concern. The FDA labeling lists potential fetal harm.

What This Means for You Practically

If you are prescribed spironolactone for acne and you have any chance of becoming pregnant, you need reliable contraception for the entire time you are taking it. Most dermatologists and women's health clinicians recommend a combined oral contraceptive pill, an IUD, or another highly effective method. Barrier methods alone (condoms, diaphragm) are not considered sufficient given the teratogenic risk.

If you discover you are pregnant while taking spironolactone, stop the medication immediately and contact your obstetric provider. A single inadvertent early exposure is unlikely to cause harm, but the drug should not be continued into the second or third trimester under any circumstances.

Lactation

Spironolactone and its metabolite canrenone are excreted into breast milk. The relative infant dose is estimated to be low in absolute terms, but there are no strong safety studies in nursing infants, and the theoretical risk of anti-androgenic effects on a male infant's hormonal development has not been formally evaluated. The standard recommendation is to avoid spironolactone while breastfeeding and discuss alternatives, such as topical retinoids or azelaic acid, with your provider.

Postpartum Acne

Postpartum hormonal shifts can trigger significant acne flares, sometimes worse than anything a woman experienced before pregnancy. In the postpartum period, if you are not breastfeeding, spironolactone can be restarted alongside reliable contraception once your clinician confirms you are not pregnant.

Who This Drug Is Right For, and Who Should Think Twice

Spironolactone is not a one-size-fits-all answer to acne, and framing it by life stage and condition is more useful than listing abstract contraindications.

Women Likely to Benefit Most

• Adult women with acne predominantly on the lower face, jaw, chin, or neck
• Women whose acne worsens in the week before their period (premenstrual flare pattern)
• Women with PCOS who have both acne and hirsutism (dual benefit)
• Women who have failed topical retinoids, antibiotics, or benzoyl peroxide
• Perimenopausal women with new-onset or worsening jawline acne not explained by another cause
• Women who cannot or do not wish to use oral isotretinoin

Women Who Should Approach With Caution or Avoid

• Anyone pregnant or planning pregnancy within one to two months
• Women who are breastfeeding
• Women with chronic kidney disease or significantly reduced kidney function (hyperkalemia risk)
• Women taking other potassium-sparing agents or high-dose ACE inhibitors without monitoring
• Women with a personal history of breast cancer (spironolactone has weak estrogenic activity; the clinical significance is debated, but caution is warranted pending more data)
• Women with Addison's disease or other conditions involving impaired aldosterone function

Dosing, Timing, and What to Expect

Starting at 50 mg per day with food reduces the likelihood of dizziness or nausea. Most clinicians assess response at 8 to 12 weeks before escalating. The evidence from Layton et al. suggests that 100 to 200 mg per day achieves the strongest acne benefit. Doses above 100 mg per day carry higher rates of menstrual irregularity, breast tenderness, and polyuria, and those side effects are dose-dependent.

Acne improvement is not instant. Most women see meaningful change between weeks 8 and 16. Full clearance may take up to 6 months. If you are also starting a combined oral contraceptive at the same time, some of the early improvement may be attributable to the OCP rather than to spironolactone specifically, and it can be difficult to disentangle the contributions.

Monitoring: your prescriber will check serum potassium, ideally at baseline and again at 4 to 8 weeks, particularly if you are on ACE inhibitors, ARBs, or have any renal function concerns. In otherwise healthy young women taking spironolactone at standard acne doses (50 to 100 mg per day), clinically significant hyperkalemia is uncommon, but the check is still standard of care.

From Aldosterone to Acne: Why This Drug's Journey Matters

Spironolactone's path from a 1957 cardiovascular compound to a first-line hormonal acne treatment for women is, at its core, a story about androgen biology in female skin. The drug works because adult female acne is, in most cases, an androgen-sensitivity problem. Sebaceous glands in women respond to androgens just as they do in men, often more than the bloodwork suggests, and a compound that blocks that signal at the receptor level produces real, measurable skin improvement.

The fact that this happened through clinical observation rather than planned drug development also matters. It means the evidence base, while solid for the core indication, still has meaningful gaps: limited pharmacokinetic data specific to women across the menstrual cycle, almost no prospective trial data in perimenopausal women, and no head-to-head RCT comparing spironolactone to isotretinoin in adult female hormonal acne at the scale that would settle the question definitively. A 2021 systematic review in JAAD identified exactly these gaps and called for adequately powered RCTs in women across life stages. Those trials are still underway.

What is not in dispute: for the right woman, at the right life stage, with appropriate contraception in place, spironolactone at 50 to 200 mg per day addresses the hormonal root of acne in a way that topical treatments and antibiotics simply cannot.